Concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer

S. H. Cho, H. J. Shim, Se Ryeon Lee, J. S. Ahn, D. H. Yang, Y. K. Kim, T. K. Nam, J. J. Lee, H. J. Kim, Ik Joo Chung

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

How best to manage advanced esophageal cancer remains unresolved, especially in palliative care. Here, in a pilot study, we evaluated the efficacy and safety of concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer. Patients with locally advanced or metastatic squamous cell carcinoma of the esophagus received S-1 and cisplatin at doses of 70 mg/m2/day for 14 days and 70 mg/m2 on day 1, respectively, every 3 weeks. Concurrently, radiotherapy was started at a dose of 200 cGy/day, up to a total of 5400 cGy. After concurrent chemoradiotherapy, additive chemotherapy was repeated up to six cycles. Thirty patients were enrolled in this study; of the 27 in whom efficacy could be evaluated, an objective response rate was seen in 20 (74.1%), including five (18.5%) complete pathologic responses in primary lesions. Improvement of dysphagia was seen in 21 (76%) patients. In patients with stage II or III esophageal cancer, the median progression-free survival and overall survival were 10.6 ± 0.6 months (95% CI: 9.4-11.8) and 23.0 ± 5.1 months (95% CI: 13.0-32.9), respectively. In patients with stage IV esophageal cancer, the median progression-free survival and overall survival were 5.4 ± 1.6 months (95% CI: 2.2-8.6) and 11.6 ± 1.6 months (95% CI: 8.4-14.8), respectively. The main hematological toxicity was neutropenia, but no neutropenic fever was observed. The major non-hematological toxicities were asthenia and vomiting, mostly of grades 1 and 2. Thus, concurrent chemoradiotherapy with S-1 and cisplatin may be a promising nonsurgical treatment in advanced esophageal cancer.

Original languageEnglish
Pages (from-to)697-703
Number of pages7
JournalDiseases of the Esophagus
Volume21
Issue number8
DOIs
Publication statusPublished - 2008 Nov 24
Externally publishedYes

Fingerprint

Chemoradiotherapy
Esophageal Neoplasms
Cisplatin
Disease-Free Survival
Asthenia
Survival
Deglutition Disorders
Neutropenia
Palliative Care
Esophagus
Vomiting
Squamous Cell Carcinoma
Fever
Radiotherapy
Safety
Drug Therapy

Keywords

  • Chemoradiotherapy
  • Cisplatin
  • Esophageal cancer
  • S-1

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer. / Cho, S. H.; Shim, H. J.; Lee, Se Ryeon; Ahn, J. S.; Yang, D. H.; Kim, Y. K.; Nam, T. K.; Lee, J. J.; Kim, H. J.; Chung, Ik Joo.

In: Diseases of the Esophagus, Vol. 21, No. 8, 24.11.2008, p. 697-703.

Research output: Contribution to journalArticle

Cho, SH, Shim, HJ, Lee, SR, Ahn, JS, Yang, DH, Kim, YK, Nam, TK, Lee, JJ, Kim, HJ & Chung, IJ 2008, 'Concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer', Diseases of the Esophagus, vol. 21, no. 8, pp. 697-703. https://doi.org/10.1111/j.1442-2050.2008.00837.x
Cho, S. H. ; Shim, H. J. ; Lee, Se Ryeon ; Ahn, J. S. ; Yang, D. H. ; Kim, Y. K. ; Nam, T. K. ; Lee, J. J. ; Kim, H. J. ; Chung, Ik Joo. / Concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer. In: Diseases of the Esophagus. 2008 ; Vol. 21, No. 8. pp. 697-703.
@article{fb009cdbdea1499c97fdc1a7a4860123,
title = "Concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer",
abstract = "How best to manage advanced esophageal cancer remains unresolved, especially in palliative care. Here, in a pilot study, we evaluated the efficacy and safety of concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer. Patients with locally advanced or metastatic squamous cell carcinoma of the esophagus received S-1 and cisplatin at doses of 70 mg/m2/day for 14 days and 70 mg/m2 on day 1, respectively, every 3 weeks. Concurrently, radiotherapy was started at a dose of 200 cGy/day, up to a total of 5400 cGy. After concurrent chemoradiotherapy, additive chemotherapy was repeated up to six cycles. Thirty patients were enrolled in this study; of the 27 in whom efficacy could be evaluated, an objective response rate was seen in 20 (74.1{\%}), including five (18.5{\%}) complete pathologic responses in primary lesions. Improvement of dysphagia was seen in 21 (76{\%}) patients. In patients with stage II or III esophageal cancer, the median progression-free survival and overall survival were 10.6 ± 0.6 months (95{\%} CI: 9.4-11.8) and 23.0 ± 5.1 months (95{\%} CI: 13.0-32.9), respectively. In patients with stage IV esophageal cancer, the median progression-free survival and overall survival were 5.4 ± 1.6 months (95{\%} CI: 2.2-8.6) and 11.6 ± 1.6 months (95{\%} CI: 8.4-14.8), respectively. The main hematological toxicity was neutropenia, but no neutropenic fever was observed. The major non-hematological toxicities were asthenia and vomiting, mostly of grades 1 and 2. Thus, concurrent chemoradiotherapy with S-1 and cisplatin may be a promising nonsurgical treatment in advanced esophageal cancer.",
keywords = "Chemoradiotherapy, Cisplatin, Esophageal cancer, S-1",
author = "Cho, {S. H.} and Shim, {H. J.} and Lee, {Se Ryeon} and Ahn, {J. S.} and Yang, {D. H.} and Kim, {Y. K.} and Nam, {T. K.} and Lee, {J. J.} and Kim, {H. J.} and Chung, {Ik Joo}",
year = "2008",
month = "11",
day = "24",
doi = "10.1111/j.1442-2050.2008.00837.x",
language = "English",
volume = "21",
pages = "697--703",
journal = "Diseases of the Esophagus",
issn = "1120-8694",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer

AU - Cho, S. H.

AU - Shim, H. J.

AU - Lee, Se Ryeon

AU - Ahn, J. S.

AU - Yang, D. H.

AU - Kim, Y. K.

AU - Nam, T. K.

AU - Lee, J. J.

AU - Kim, H. J.

AU - Chung, Ik Joo

PY - 2008/11/24

Y1 - 2008/11/24

N2 - How best to manage advanced esophageal cancer remains unresolved, especially in palliative care. Here, in a pilot study, we evaluated the efficacy and safety of concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer. Patients with locally advanced or metastatic squamous cell carcinoma of the esophagus received S-1 and cisplatin at doses of 70 mg/m2/day for 14 days and 70 mg/m2 on day 1, respectively, every 3 weeks. Concurrently, radiotherapy was started at a dose of 200 cGy/day, up to a total of 5400 cGy. After concurrent chemoradiotherapy, additive chemotherapy was repeated up to six cycles. Thirty patients were enrolled in this study; of the 27 in whom efficacy could be evaluated, an objective response rate was seen in 20 (74.1%), including five (18.5%) complete pathologic responses in primary lesions. Improvement of dysphagia was seen in 21 (76%) patients. In patients with stage II or III esophageal cancer, the median progression-free survival and overall survival were 10.6 ± 0.6 months (95% CI: 9.4-11.8) and 23.0 ± 5.1 months (95% CI: 13.0-32.9), respectively. In patients with stage IV esophageal cancer, the median progression-free survival and overall survival were 5.4 ± 1.6 months (95% CI: 2.2-8.6) and 11.6 ± 1.6 months (95% CI: 8.4-14.8), respectively. The main hematological toxicity was neutropenia, but no neutropenic fever was observed. The major non-hematological toxicities were asthenia and vomiting, mostly of grades 1 and 2. Thus, concurrent chemoradiotherapy with S-1 and cisplatin may be a promising nonsurgical treatment in advanced esophageal cancer.

AB - How best to manage advanced esophageal cancer remains unresolved, especially in palliative care. Here, in a pilot study, we evaluated the efficacy and safety of concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer. Patients with locally advanced or metastatic squamous cell carcinoma of the esophagus received S-1 and cisplatin at doses of 70 mg/m2/day for 14 days and 70 mg/m2 on day 1, respectively, every 3 weeks. Concurrently, radiotherapy was started at a dose of 200 cGy/day, up to a total of 5400 cGy. After concurrent chemoradiotherapy, additive chemotherapy was repeated up to six cycles. Thirty patients were enrolled in this study; of the 27 in whom efficacy could be evaluated, an objective response rate was seen in 20 (74.1%), including five (18.5%) complete pathologic responses in primary lesions. Improvement of dysphagia was seen in 21 (76%) patients. In patients with stage II or III esophageal cancer, the median progression-free survival and overall survival were 10.6 ± 0.6 months (95% CI: 9.4-11.8) and 23.0 ± 5.1 months (95% CI: 13.0-32.9), respectively. In patients with stage IV esophageal cancer, the median progression-free survival and overall survival were 5.4 ± 1.6 months (95% CI: 2.2-8.6) and 11.6 ± 1.6 months (95% CI: 8.4-14.8), respectively. The main hematological toxicity was neutropenia, but no neutropenic fever was observed. The major non-hematological toxicities were asthenia and vomiting, mostly of grades 1 and 2. Thus, concurrent chemoradiotherapy with S-1 and cisplatin may be a promising nonsurgical treatment in advanced esophageal cancer.

KW - Chemoradiotherapy

KW - Cisplatin

KW - Esophageal cancer

KW - S-1

UR - http://www.scopus.com/inward/record.url?scp=55249113352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55249113352&partnerID=8YFLogxK

U2 - 10.1111/j.1442-2050.2008.00837.x

DO - 10.1111/j.1442-2050.2008.00837.x

M3 - Article

C2 - 18522639

AN - SCOPUS:55249113352

VL - 21

SP - 697

EP - 703

JO - Diseases of the Esophagus

JF - Diseases of the Esophagus

SN - 1120-8694

IS - 8

ER -